Business context and reporting period
Tilray Brands, Inc. filed this unaudited Form 10-Q for the quarter ended February 28, 2023. The company reports four segments: cannabis, distribution, beverage alcohol and wellness. Amounts below are in U.S. dollars; financial statement amounts are generally in millions unless stated otherwise.
Financial performance and position
| Metric | Q3 FY2023 | Comparable period |
|---|---|---|
| Net revenue | $145.6 million | $151.9 million, down 4% |
| Gross profit (loss) and margin | $(11.7) million; (8)% | $39.8 million; 26% |
| Net income (loss) | $(1,195.8) million; $(1.90) per share | $52.5 million; $0.09 per share |
| Adjusted EBITDA (non-GAAP) | $14.0 million | $10.1 million |
| Adjusted gross profit and margin (non-GAAP) | $44.3 million; 30% | $39.8 million; 26% |
- For the nine months ended February 28, revenue was $442.9 million, down 7%; net loss was $1,323.2 million versus net income of $23.7 million; operating cash used was $35.7 million versus $156.7 million. Nine-month adjusted EBITDA was $39.3 million versus $36.5 million.
- Q3 segment revenue: cannabis $47.5 million (down 14%); distribution $65.4 million (up 5%); beverage alcohol $20.6 million (up 5%); wellness $12.0 million (down 18%). Cannabis, distribution and wellness comparisons reflect reported U.S.-dollar results.
- Cash and cash equivalents were $165.0 million at quarter-end; marketable securities were $243.3 million, for combined cash and marketable securities of $408.3 million. Cash fell $250.9 million from May 31, 2022, including $243.2 million invested in marketable securities.
- Working capital was $288.8 million, compared with $413.4 million at February 28, 2022. Current assets were $758.5 million and current liabilities $469.7 million at quarter-end.
- Long-term debt carrying value was $167.3 million; convertible debentures payable totaled $407.2 million, including $184.1 million classified as current; bank indebtedness was $18.1 million. The company reported compliance with its long-term debt covenants.
Material changes versus the prior comparable period
- Q3 gross profit swung to a loss as cost of goods sold rose 40% while revenue declined 4%. The quarter included a $55.0 million inventory valuation charge after management decided to repurpose some dried cannabis inventory; the charge was non-cash.
- The company recorded $1,115.4 million of non-cash impairments, versus none in Q3 FY2022. The charges included $618.5 million of goodwill, $205.0 million of intangible assets, $104.0 million of capital assets, $181.4 million of convertible notes receivable and $6.5 million of other current assets.
- Cannabis revenue fell amid price compression, market-share and product-mix pressures, and lower international sales. The HEXO advisory arrangement contributed $8.7 million of Q3 and $24.3 million of nine-month cannabis revenue. Excluding that advisory revenue, management reported adjusted cannabis gross margins of 35% for Q3 and 37% for the nine months.
- Beverage alcohol revenue grew, primarily reflecting the Montauk acquisition, but segment gross margins declined as acquired businesses operate at lower margins and SweetWater’s Colorado expansion remained in start-up. Distribution’s Q3 gross margin improved to 11% from 8%, reflecting a shift toward higher-margin sales.
- Shares issued and outstanding increased from 532.7 million at May 31, 2022 to approximately 617.9 million at February 28, 2023. The increase included ATM issuances, shares issued for the HEXO note purchase and other transactions.
Outlook, management commentary, risks and unusual items
- No consolidated revenue or earnings guidance is stated in the filing. Management said it is prioritizing positive operating cash flow and free-cash-flow generation, reducing production, headcount and discretionary costs in response to delayed legalization and market conditions.
- Management reported $22.0 million of the cannabis cost-optimization plan achieved on an annualized run-rate basis, including $12.0 million of realized savings during the period, toward a $30 million plan. It also said the $100 million annualized Tilray-Aphria synergy target had been achieved.
- For the first 12 months of its HEXO arrangements, Tilray expected to earn approximately $40 million: $31 million of adult-use cannabis revenue and $9 million of interest income. The filing also describes risks to the HEXO note: HEXO had raised a going-concern issue regarding its ability to meet a minimum liquidity covenant, and Tilray recorded a $63.6 million note impairment.
- Goodwill and other asset valuations remain sensitive to assumptions. The filing cites rising interest rates, market capitalization below carrying value, slower-than-expected legalization and market-share declines. Management’s sensitivity analysis indicates that a 1 percentage-point increase in the cannabis goodwill discount rate would result in an additional $300 million impairment.
- The $39.9 million settlement of Tilray reorganization litigation was approved February 27, 2023; proceeds were received after quarter-end. The company recorded a net litigation recovery in the period. Other disclosed matters include securities and commercial litigation; outcomes are uncertain.
- Subsequent to quarter-end, stockholders approved charter amendments on March 16, 2023. On April 10, 2023, Tilray entered an agreement to acquire HEXO in a share exchange, subject to closing conditions; each HEXO share is to be exchanged for 0.4352 Tilray common shares.
- Near-term debt and liquidity warrant attention: the TLRY 23 notes mature October 2023, and the HTI convertible note has a September 2023 maturity. The filing reports $449.1 million of scheduled convertible-note principal payments across the listed commitment periods.
Important facts for investors to verify
- Reconcile the $1.12 billion impairment total, especially the valuation assumptions and exposure to further write-downs in goodwill, intangible assets and convertible notes.
- Assess the quality and durability of reported adjusted EBITDA and adjusted gross margins, including the effect of excluded impairment, inventory, transaction, litigation and other adjustments.
- Review cash generation and available liquidity alongside upcoming convertible-note maturities, debt repayments and the completed ATM program; distinguish cash from marketable securities.
- Track HEXO’s liquidity and performance, Tilray’s ability to collect on its note and realize advisory fees and cost savings, and the closing and integration risks of the subsequent HEXO arrangement.
- Monitor Canadian cannabis pricing, excise-tax burdens, market share and inventory; verify whether planned production reductions and cost savings translate into sustainable cash flow.
- Consider dilution from equity issuances and the potential share impact of the HEXO transaction, convertibles, warrants and other equity-linked instruments.
- Review the status and potential exposure of disclosed litigation and contingencies; the filing does not quantify a clear maximum exposure for several proceedings.